

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/416,902
		Filing Date	October 13, 1999
		First Named Inventor	John M. McCafferty
		Group Art Unit	1639
Examiner Name	Amber D. Steele		
Attorney Docket Number	05569.0004.DVUS06		
Sheet	1	of	11

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	4,704,692	11/03/1987	Ladner	
	A2	5,258,289	11/02/1993	Davis, et al.	
	A3	5,260,203	11/09/1993	Ladner, et al.	
	A4	5,534,617	07/09/1996	Cunningham, et al.	
	A5	5,567,610	10/22/1996	Borrebaeck, et al.	
	A6	5,580,717	12/03/1996	Dower, et al.	
	A7	5,698,426	12/16/1997	Huse	
	A8	5,780,225	07/14/1998	Wigler, et al.	
	A9	5,814,476	09/29/1998	Kauffman, et al.	
	A10	5,837,500	11/17/1998	Ladner, et al.	
	A11	5,840,479	11/24/1998	Little, et al.	
	A12	5,855,885	01/05/1999	Smith, et al.	
	A13	5,935,823	08/10/1999	Fowlkes, et al.	
	A14	5,948,635	09/07/1999	Kay, et al.	
	A15	5,955,358	09/21/1999	Huse	
	A16	5,969,108	10/19/1999	McCafferty, et al.	
	A17	6,172,197	01/09/2001	McCafferty, et al.	
	A18	6,225,447	05/01/2001	Winter, et al.	
	A19	6,291,650	09/18/2001	Winter, et al.	
	A20	6,593,081	07/15/2003	Griffiths, et al.	
	A21	7,063,943	06/20/2006	McCafferty, et al.	

U.S. PUBLICATION DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/416,902
				Filing Date	October 13, 1999
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	2	of	11	Attorney Docket Number	05569.0004.DVUS06

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)					
	B1	EP 436597 B1		04/02/1997	Protein Engineering Corporation		
	B2	GB 91/25579.4		02/12/1991	Cambridge Antibody Technology Ltd.		
	B3	GB 91/25582.8		02/12/1991	Cambridge Antibody Technology Ltd.		
	B4	WO 92-01047		01/23/1992	Cambridge Antibody Technology Ltd.		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	C1	U.S. Appl. No. 08/484,893 Advisory Action dated November 3, 1997	
	C2	U.S. Appl. No. 08/484,893 Final office action dated March 28, 1997	
	C3	U.S. Appl. No. 08/484,893 Non-final office action dated July 20, 1999	
	C4	U.S. Appl. No. 08/484,893 Non-Final office action dated June 17, 1996	
	C5	U.S. Appl. No. 08/484,893 Non-final office action dated June 9, 1998	
	C6	U.S. Appl. No. 08/484,893 Notice of Allowance dated March 29, 2000	
	C7	U.S. Appl. No. 08/484,893 Restriction Requirement dated December 7, 1998	
	C8	U.S. Appl. No. 09/196,522 Examiner's Amendment dated January 28, 2004	
	C9	U.S. Appl. No. 09/196,522 Restriction Requirement dated November 27, 1999	
	C10	U.S. Appl. No. 09/196,522 Non-final office action dated April 20, 2000	
	C11	U.S. Appl. No. 09/196,522 Non-final office action dated January 3, 2001	
	C12	U.S. Appl. No. 09/196,522 Notice of Allowance dated May 3, 2004	
	C13	U.S. Appl. No. 09/196,586 Advisory Action dated December 5, 2008	
	C14	U.S. Appl. No. 09/196,586 Advisory Action dated May 4, 2007	
	C15	U.S. Appl. No. 09/196,586 Final office action dated September 22, 2006	
	C16	U.S. Appl. No. 09/196,586 Final office action dated April 17, 2001	
	C17	U.S. Appl. No. 09/196,586 Final office action dated December 22, 2004	
	C18	U.S. Appl. No. 09/196,586 Final office action dated September 15, 2008	
	C19	U.S. Appl. No. 09/196,586 Non final office action dated April 10, 2000	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/416,902
				Filing Date	October 13, 1999
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	3	of	11	Attorney Docket Number	05569.0004.DVUS06

	C20	U.S. Appl. No. 09/196,586 Non-final office action dated April 4, 2002	
	C21	U.S. Appl. No. 09/196,586 Non-final office action dated December 28, 2005	
	C22	U.S. Appl. No. 09/196,586 Non-Final office action dated January 9, 2008	
	C23	U.S. Appl. No. 09/196,586 Non-final office action dated May 19, 2004	
	C24	U.S. Appl. No. 09/196,586 Restriction Requirement dated December 21, 1999	
	C25	U.S. Appl. No. 09/196,673 Advisory Action dated November 6, 2002	
	C26	U.S. Appl. No. 09/196,673 Advisory Action dated March 24, 2003	
	C27	U.S. Appl. No. 09/196,673 Final office action dated December 22, 2004	
	C28	U.S. Appl. No. 09/196,673 Final office action dated May 14, 2002	
	C29	U.S. Appl. No. 09/196,673 Non-final office action dated April 11, 2000	
	C30	U.S. Appl. No. 09/196,673 Non-final office action dated January 18, 2001	
	C31	U.S. Appl. No. 09/196,673 Non-final office action dated March 4, 2004	
	C32	U.S. Appl. No. 09/196,673 Notice of Allowance dated November 3, 2005	
	C33	U.S. Appl. No. 09/196,673 Restriction Requirement dated December 21, 1999	
	C34	U.S. Appl. No. 09/309,639 Non-final office action dated January 3, 2001	
	C35	U.S. Appl. No. 09/309,639 Official communication dated August 22, 2003	
	C36	U.S. Appl. No. 09/309,639 Restriction Requirement dated September 1, 2000	
	C37	U.S. Appl. No. 09/417,478 Advisory Action dated January 29, 2007	
	C38	U.S. Appl. No. 09/417,478 Final office action dated April 1, 2009	
	C39	U.S. Appl. No. 09/417,478 Final office action dated December 14, 2007	
	C40	U.S. Appl. No. 09/417,478 Final office action dated July 5, 2006	
	C41	U.S. Appl. No. 09/417,478 Non-final office action dated January 20, 2000	
	C42	U.S. Appl. No. 09/417,478 Non-final office action dated June 12, 2008	
	C43	U.S. Appl. No. 09/417,478 Non-final office action dated May 17, 2007	
	C44	U.S. Appl. No. 09/417,478 Non-final office action dated November 20, 2000	
	C45	U.S. Appl. No. 09/417,479 Non-final office action dated May 3, 2006	
	C46	U.S. Appl. No. 09/417,479 Restriction Requirement dated June 26, 2000	
	C47	U.S. Appl. No. 09/706,507 Non-final office action dated May 5, 2006	
	C48	U.S. Appl. No. 09/706,507 Restriction Requirement dated May 21, 2001	
	C49	U.S. Appl. No. 09/726,219 Non-final office action dated August 12, 2003	
	C50	U.S. Appl. No. 09/726,219 Notice of Allowance dated February 25, 2004	
	C51	U.S. Appl. No. 09/726,219 Restriction Requirement dated March 12, 2003	
	C52	U.S. Appl. No. 09/971,857 Advisory Action dated August 15, 1996	
	C53	U.S. Appl. No. 09/971,857 Examiner's Interview Summary Record dated December 13, 1996	
	C54	U.S. Appl. No. 09/971,857 Examiner's Interview summary Record dated April 24, 1997	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/416,902
				Filing Date	October 13, 1999
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
(use as many sheets as necessary)				Attorney Docket Number	05569.0004.DVUS06
Sheet	4	of	11		

	C55	U.S. Appl. No. 09/971,857 Final office action dated April 23, 1996	
	C56	U.S. Appl. No. 09/971,857 Non-final office action dated June 30, 1995	
	C57	U.S. Appl. No. 09/971,857 Notice of Allowance dated July 23, 1997	
	C58	U.S. Appl. No. 09/971,857 Response to 312 Amendment dated April 20, 1999	
	C59	U.S. Appl. No. 10/803,622 Examiner's Interview Summary dated March 20, 2008	
	C60	U.S. Appl. No. 10/803,622 Advisory Action dated July 31, 2007	
	C61	U.S. Appl. No. 10/803,622 Final office action dated April 10, 2007	
	C62	U.S. Appl. No. 10/803,622 Final office action dated February 17, 2009	
	C63	U.S. Appl. No. 10/803,622 Non-final office action dated July 3, 2008	
	C64	U.S. Appl. No. 10/803,622 Non-final office action dated July 5, 2006	
	C65	U.S. Appl. No. 10/803,622 Non-final office action dated October 2, 2007	
	C66	U.S. Appl. No. 10/803,622 Restriction Requirement dated April 10, 2006	
	C67	U.S. Appl. No. 10/803,653 Advisory Action dated October 11, 2007	
	C68	U.S. Appl. No. 10/803,653 Final office action dated May 8, 2007	
	C69	U.S. Appl. No. 10/803,653 Final office action dated November 5, 2008	
	C70	U.S. Appl. No. 10/803,653 Non-final office action dated January 18, 2008	
	C71	U.S. Appl. No. 10/803,653 Non-final office action dated October 4, 2006	
	C72	U.S. Appl. No. 10/803,653 Notice of Allowance dated May 21, 2009	
	C73	U.S. Appl. No. 11/555,464 Non-final office action dated March 5, 2009	
	C74	U.S. Appl. No. 11/555,519 Non-final office action dated March 5, 2009	
	C75	Abbas, et al. , "Cellular and Molecular Immunology," Saunders, Third Edition, p. 412 (1997)	
	C76	Alberts, et al. , "Molecular Biology of the Cell," Garland Publications, Third Edition, p. 96 (1994)	
	C77	Avrameas and Ternynck , "Natural Antibodies," in Delves, P., and I. Roitt, The Encyclopedia of Immunology, Second Edition, Academic Press, pp. 1806-1809 (1998)	
	C78	Barbas, et al. , "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site," Proc. Natl. Acad. Sci. (USA), Vol. 88, pp. 7978-7982 (1991)	
	C79	Barbas, et al. , "Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen Specific Fabs," Methods: Companion Methods Enzymol., Vol. 2, pp. 119 (1991)	
	C80	Beidler, et al. , "Cloning and High Level Expression of a Chimeric Antibody with Specificity for Human Carcinoembryonic Antigen," J. Immunology, Vol. 141, pp. 4053-4060 (1988)	
	C81	Berborowicz and Jaroszewski , "Carcinoembryonic Antigen as an Autoantigen," Immunol. Ser., Vol. 52, pp. 65-83 (1982)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/416,902
				Filing Date	October 13, 1999
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
(use as many sheets as necessary)				Attorney Docket Number	05569.0004.DVUS06
Sheet	5	of	11		

	C82	Berzofsky, et al. , "Antigen-Antibody Interactions and Monoclonal Antibodies," in Paul, W., Fundamental Immunology, Second Edition, Chapter 12, pp. 332 (see also, Fourth Edition, 1994 (1999) Chapter 4, p. 91)	
	C83	Beste, G., et al. , "Small Antibody-like Proteins with Prescribed Ligand Specificities Derived from the Lipocalin Fold," Sci. USA, Vol. 96, No. 5, pp. 1898-19903, ISSN 0027-8424 (1999) Abstract	
	C84	Boerner, et al. , "Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-Primed Human (Splenocytes)," J. Immunol. Vol. 147, pp. 86-95 (1991)	
	C85	Breitling, et al. , "A Surface Expression Vector for Antibody Screening," Gene, Vol. 104, pp. 147-153 (1991)	
	C86	Buck, Cell Biology , Vol. 3, pp. 179-188 (1992)	
	C87	Burton, et al. , "A Large Array of Human Monoclonal Antibodies to Type 1 Human Immunodeficiency Virus from Combinatorial Libraries of Asymptomatic Seropositive Individuals," Proc. Natl. Acad. Sci., Vol. 88, pp. 10134-10137 (1991)	
	C88	Casali and Notkins , "Probing the Human [B-cell] Repertoire with EBV: Polyreactive Antibodies and CD5+ B Lymphocytes," Ann. Rev. Immunol., Vol. 7, pp. 513-535 (1989)	
	C89	Chang, et al. , "Expression of Antibody Fab Domains on Bacteriophage Surfaces: Potential Use of Antibody Selection," J. Immunol., Vol. 1047, pp. 3610-3614 (1991)	
	C90	Cohen, P. L. , "Systemic Autoimmunity," in Paul, W., Fundamental Immunology, Fourth Edition, Lippincott-Raven, p. 1608 (1997).	
	C91	Delves, P.J. , "Autoimmunity," in Delves, P. and I. Roitt, The Encyclopedia of Immunology, Second Edition, Academic Press, p. 292 (1998)	
	C92	Dighiero, et al. , "Naturally Occurring Autoantibodies Against Nine Common Antigens in Human Sera," J. Immunol., Vol. 218, No. 128, pp. 2788-2792 (1982)	
	C93	Fomsgaard, et al. , "Auto-antibodies to Tumor Necrosis Factor in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections," Scand. J. Immunol., Vol. 30, pp. 219-223 (1989)	
	C94	Geysen, H.M., et al. , "A Priori Delineation of a Peptide Which Mimics a Discontinuous Antigenic Determinant," Molecular Immunology, Vol. 23, No. 7, pp. 709-715 (1986)	
	C95	Golub, E. , "The Limits of Medicine: How Science Shapes our Hope for the Cure," Times Books/Random House, p. 117-120 (1994)	
	C96	Golub, E., and Green, D. , "Immunology: A Synthesis," Sinauer Associates, Second Edition, p. 531 (1991)	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/416,902
				Filing Date	October 13, 1999
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
(use as many sheets as necessary)				Attorney Docket Number	05569.0004.DVUS06
Sheet	6	of	11		

C97	Goodnow, et al. , "Altered Immunoglobulin Expression and Functional Silencing of Self-Reactive B Lymphocytes in Transgenic Mice," <i>Nature</i> , Vol. 334, pp. 676-682 (1988)	
C98	Gram, et al. , "In vitro Selection and Affinity Maturation of Antibodies from a Naïve Combinatorial Immunoglobulin Library," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 3576-3580 (1992)	
C99	Griffiths, et al. , "Human Anti-Self Antibodies with High Specificity from Phage Display Libraries," <i>EMBO J.</i> , Vol. 12, pp. 725-734 (1993)	
C100	Griffiths, et al. , "Isolation of High Affinity Human Antibodies Directly from Large Synthetic Repertoires," <i>EMBO J.</i> , Vol. 13, pp. 3245-3260 (1994)	
C101	Guilbert, et al. , "Naturally Occurring Antibodies Against Nine Common Antigens in Human Sera," <i>J. Immunol.</i> , Vol. 128, pp. 2779-2787 (1982)	
C102	Hartley, O. , "The Use of Phage Display in the Study of Receptors and Their Ligands," <i>J. of Receptors and Signal Transduction</i> , Vol. 22, Nos. 1-4, pp. 373-393 (2002)	
C103	Hartman and Wright , "Identification of Autoantibodies Specific for the Neutrophil Adhesion Glycoproteins CD11b/CD18 in Patients with Autoimmune Disease (Neutroenia," <i>Blood</i> , Vol. 78, pp. 1096-1104 (1991)	
C104	Hirohata, et al. , "Frequency Analysis of Human Peripheral Blood B Cells Producing IGM-Rheumatoid Factor," <i>J. Immunol.</i> , Vol. 145, pp. 1681-1686 (1990)	
C105	Holness, et al. , <i>Journal of Cell Science</i> , Vol. 107, pp. 2065-2070 (1994)	
C106	Hoogenboom, et al. , "Building Antibodies from their Genes," <i>Rev. Fr. Transfus. Hemobiol.</i> , Vol. 36, pp. 19-47 (1993)	
C107	Hoogenboom, et al. , "Multi-Subunit Proteins on the Surface of Filamentous Phage: Methodologies for Displaying Antibody (Fab) Heavy and Light Chains," <i>Nucl. Acids Res.</i> , Vol. 19, pp. 4133-4137 (1991)	
C108	Huse , "Combinatorial Antibody Expression Libraries in Filamentous Phage," Chapter 5 of <i>Antibody Engineer, Borrebaeck (ed.)</i> , W.H. Freeman and Co. N.Y. (1992)	
C109	International Search Report of European Patent Application No. 04005419.9 dated August 9, 2004	
C110	Jacobsson, K., et al. , "Shot-gun Phage Display Mapping of Two Streptococcal Cell-Surface Proteins," <i>Microbial Research</i> , Vol. 152, No. 2, pp. 121-128, ISSN 0944-4013 (1997) Abstract	
C111	Kaushik, et al. , "Comparative Analysis of Natural Antibody Specificities Among Hybridomas Originating from Spleen and Peritoneal Cavity of Adult NZB and BALB/c Mince," <i>Scand. J. Immunol.</i> , Vol. 27, pp. 461-471 (1988)	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/416,902
				Filing Date	October 13, 1999
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	7	of	11	Attorney Docket Number	05569.0004.DVUS06

	C112	Klein and Horejsi , "Immunology" [Chapter 20, "Immunological Tolerance"], Blackwell Scientific, Second Edition, p. 527 (1997)	
	C113	Koga, et al. , "Mouse-Human Chimeric Monoclonal Antibody to Carcinoembryonic Antigen (CEA): In Vitro and In Vivo Activities," Hybridoma, Vol. 9, pp. 43-56 (1990)	
	C114	Landsteiner, K. , "The Specificity of the Immune Response," quoted in Golub, E., Immunology: A Synthesis, Sinauer Associates, p. 19-25 [1991 book] (1987)	
	C115	Lehninger, et al. , Principles of Biochemistry, 2nd ed., Title Page, copy right page and p. G-4 only (1993)	
	C116	Lobel, L.I., et al. , "Filamentous Phage Displaying the Extracellular Domain of the hLH/CG Receptor Bind hCG Specifically," Endocrinology, Vol. 138, No. 3, pp. 1232-1239, ISSN: 0013-7227 (1997) Abstract	
	C117	Logtenberg, et al. , "Analysis of the Human Tonsil B Cell Repertoire by Somatic Hybridization: Occurrence of Both "Monospecific" and "Multispecific" (auto) Antibody-Secreting Cells," Eur. J. Immunol., Vol. 17, pp. 855-859 (1987)	
	C118	Lydyard, et al. , "The Antibody Repertoire of Early Human B Cells," Scand. J. Immunol., Vol. 31, pp. 33-43 (1990)	
	C119	Mamula, et al. , "The Specificity of Human Anti-Cyclochrome c Autoantibodies that Arise in Autoimmune Disease," J. Immunol., Vol. 144, pp. 1835-1840 (1990)	
	C120	Marks, et al. , "Molecular Evolution of Proteins on Filamentous Phage," J. Biol. Chem., Vol. 267, p. 16007-16010 (1992)	
	C121	McCafferty, J., et al. , "Phage-Enzymes: Expression and Affinity Chromatography of Functional Alkaline Phosphatase on the Surface of Bacteriophage," Protein Engineering, Vol. 4, No. 8, pp. 955-961 (1991)	
	C122	McHeyzer-Williams, et al. , "Clonal Analysis of Autoantibody-Producing Cell Precursors in the Preimmune B Cell Repertoire," J. Immunol., Vol. 141, pp. 4118-4123 (1988)	
	C123	Mullinax, et al. , "Identification of Human Antibody Fragment Clones Specific For Tetanus Toxoid in a Bacteriophage λ Immunorepression Library," Proc. Natl. Acad. Sci., USA, Vol. 87, pp. 8095-8099 (1990)	
	C124	Nemazee and Burk , "Clonal Deletion of B Lymphocytes in a Transgenic Mouse Bearing Anti-MHC Class I Antibody Genes," Nature, Vol. 377, pp. 562-566 (1989)	
	C125	Neumaier, et al. , "Cloning of the Genes for T84.66, an Antibody that has a High Specificity and Affinity for Carcinoembryonic Antigen, and Expression of Chimeric Human/Mouse T84.66 Genes in Myeloma and Chinese Hamster Ovary Cells," Cancer Research, Vol. 50, pp. 2128-2134 (1990)	
	C126	Nossal, G.V.J. , "Cellular Mechanisms of Immune[ologic] Tolerance," Ann. Rev. Immunol., Vol. 1, pp. 33-62 (1983)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/416,902
				Filing Date	October 13, 1999
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
(use as many sheets as necessary)				Attorney Docket Number	05569.0004.DVUS06
Sheet	8	of	11		

	C127	Nossal, G.V.J. , "Molecular and Cellular Aspects of Immunologic Tolerance," Eur. J. Biochem., Vol. 202, pp. 729-737 (1991)	
	C128	Persson, et al. , "Generation of Diverse High-Affinity Human Monoclonal Antibodies by Repertoire Cloning," Proc. Natl. Acad. Sci., Vol. 88, pp. 2432-2436 (1991)	
	C129	Portolano, S., et al. , "A Human Fab Fragment Specific For Thyroid Peroxidase Generated By Cloning Thyroid Lymphocyte-Derived Immunoglobulin Genes in a Bacteriophage Lambda Library", Biochemical and Biophysical Research Communications, Vol. 179, No. 1, pp. 372-377 (1991)	
	C130	Roitt, et al. , Immunology, Second Edition, 1989, Ivan Roitt, et al., Gower Publishing, New York, p. 51 (1989)	
	C131	Ruf., et al. , "Various Expressions of a Unique Anti-Human Thymoglobulin Antibody Repertoire in Normal State and Autoimmune Disease," Blood, Vol. 78, pp. 1096-1104 (1991)	
	C132	Smith, et al. , "Phage Display," Chem. Rev., Vol. 97, pp. 391-410 (1997)	
	C133	Svenson, et al. , "IgG Autoantibodies Against Interleukin 1 α in Sera of Normal Individuals," Scand. J. Immunol., Vol. 29, pp. 489-492 (1989)	
	C134	Tomlinson, et al. , "The Repertoire of Human Germline Vh Segments (Sequences Reveals about Fifty Groups of VH Segments) with Different Hypervariable Loops," J. Mol. Biol., Vol. 227, pp. 776-798 (1992)	
	C135	Ura, et al. , "Studies on Circulating Antibody Against Carcinoembryonic Antigen (CEA) and CEA-like Antigen in Cancer Patients," Cancer Letters, Vol. 25, pp. 283-295 (1985)	
	C136	Waterhouse, et al. , "Combinatorial Infection and in Vivo Recombination: A Strategy for Making Large Phage Antibody Repertoires," Nucl. Acids Res., Vol. 21, pp. 2265-2266 (1993)	
	C137	Weidanz, J.A., et al. , "Display of Functional Alphabets Single-Chain T-Cell Receptor Molecules on the Surface of Bacteriophage," J. Immunol. Methods, Vol. 221, (1-2), pp. 59-76, ISSN 0022-1759 (1998) Abstract	
	C138	Wilson and Stanfield , "Antibody-Antigen Interactions: New Structures and New Conformational Changes," Curr. Opin. Structural Biol., Vol. 4, pp. 857-867 (1994)	
	C139	Winter, et al. , "Making Antibodies by Phage Display Technology," Annu. Rev. Immunol., Vol. 12, pp. 433-455 (1994)	
	C140	Promega Technical Bulletin, printed January 11, 2008, revised December 2006, pGEM-3ZF(+) Vector, 9 pages	
	C141	Promega Technical Bulletin, printed January 11, 2008, revised December 2006, pGEM-3ZF(-) Vector, 9 pages	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/416,902
				Filing Date	October 13, 1999
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
(use as many sheets as necessary)				Attorney Docket Number	05569.0004.DVUS06
Sheet	9	of	11		

	C142	Stratagene Instruction Manual, printed January 11, m 2008, revised 2003, pBluescript II Phagemic Vectors, 37 pages	
	C143	First Amended Complaint, Filed March 8, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (24 pages) (U.S. District Court, District of Columbia)(signed by John S. Skilton, Attorney for Plaintiff.)	
	C144	Cambridge Antibody Technology Limited's Answer to First Amended Complaint, Filed March 22, 2002 - Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia)(signed by Brian H. Corcoran, Attorney for Defendant).	
	C145	Ilichev, A.A., et al. , "M13 Filamentous Bacteriophage in Protein Engineering", Molekulyarnaya Biologiya, Vol. 24, No. 2, pp. 530-535, (March-April 1990).	
	C146	Ilichev, A.A., et al. , "M13 Filamentous Bacteriophage for Protein Engineering", Molekulyarnaya Biologiya, Vol. 24, No. 2, pp. 530-535, (March-April 1990). (In Russian with Translated Abstract)	
	C147	Redacted Agreement Between Medical Research Council and Cambridge Antibody Technology Limited and Cambridge Antibody Technology Group plc, made 01 January 1997	
	C148	Deposition Transcript of David W. Clough, taken April 19, 2002 (Morphosys AG v. Cambridge Antibody Technology Limited, U.S. District Court, Northern District of Illinois, Eastern Division).	
	C149	E.I. du Pont de Nemours v. Cetus Corp., 19 USPQ2d 1174, (DC N.Cal. 1990).	
	C150	Oddzon Products Inc. v. Just Toys Inc., 43 USPQ2d 1641(CAFC 1997).	
	C151	Deposition Transcript of George P. Smith, Ph.D., taken 14 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C152	Deposition Transcript of Dr. David Chiswell, taken 29 April 2002; Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C153	Deposition Transcript of Dr. Gregory Paul Winter, taken April 30, 2002; Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C154	Vol. I - Deposition Transcript of Sean Malcolm Walton, taken 01 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C155	Vol. II - Deposition Transcript of Sean Malcolm Walton, taken 02 May 2002, Morphosys AG v. Cambridge Antibody Technology Limited, Case No. 1:00-CV-00146 (30 pages) (U.S. District Court, District of Columbia.)	
	C156	Chiswell memo, dated 30 July 1990, transmitting a copy of the Collaborative Agreement between Cambridge Antibody Technology and The Medical Research Council, dated July 27, 1995.	
	C157	Declaration of George P. Smith, Ph.D., Under 37 C.F.R. § 1.132, executed 30 June 1995 (submitted during the prosecution of U.S. Application No. 08/322,352).	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/416,902
				Filing Date	October 13, 1999
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
(use as many sheets as necessary)				Attorney Docket Number	05569.0004.DVUS06
Sheet	10	of	11		

	C158	Declaration of Brian K. Kay, Ph.D., executed 26 June 1998, (submitted during the prosecution of European Appln. No. 91913039.3)	
	C159	Abstract of George P. Smith, Grant No. 1R01GM41478-01A1, Project Start Date: July 1, 1989, Dept. of Health & Human Services.	
	C160	Smith Grant Application, entitled: "Filamentous Phage Physiology", dated November 1, 1988	
	C161	Administration Agreement between Cambridge Antibody Technology Ltd. and Medical Research Council, dated 01 August 1991 (Redacted).	
	C162	Fax from John McCafferty (of Cambridge Antibody Technology Limited) to Sean Walton (of Mewburn Ellis) regarding the Smith grant application.	
	C163	E-mail message from John McCafferty (of Cambridge Antibody Technology Limited) to Brian Kay regarding the Smith grant application	
	C164	Letter to Craig Panner (of the Academic Press) from John McCafferty (Cambridge Antibody Technology Limited) regarding the Smith grant application	
	C165	Fax to John McCafferty, Ph.D. (of Cambridge Antibody Technology Limited) from Craig Panner (of Academic Press) dated June 10, 1996.	
	C166	Smith, G. P., "1988 - A Year of Discovery", <i>Phage Display of Peptides and Proteins</i> , Academic Press, Inc. (1996), pp. xvii-xix.	
	C167	<u>Northern Telecom Inc. v. Datapoint Corp.</u> , 15 USPQ 1321., (CAFC 1990). Letter of Dr. Smith Re: NIH grant proposals, Dated June 27, 1997	
	C168	Barbas and Lerner "Combinatorial Immunoglobulin Libraries on the surface of phage (Phabs): rapid selection of anti-specific fabs." <i>Methods: a companion to methods in Enzymology Vol. 2</i> (2): 119-124 (1991).	
	C169	Document D91 in Appeal No. T0639/02-334: Better et al. (1988). <i>Science</i> 240, 1041-1043	
	C170	Document D92 in Appeal No. T0639/02-334: Sambrook & Russell (2001). <i>Molecular cloning: a laboratory manual 3rd Edition</i> , Cold Spring Harbor Press; particular pages 18.115 to 18.122 "Filamentous phage display"	
	C171	Document D17: Vieira and Messing (1987), <i>Methods Enzymol.</i> 153, 3-11	
	C172	Document D8: Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodology for displaying antibody (Fab) heavy and light chains," <i>Nucleic Acids Research</i> , Vol 19, No. 15 (1991), pages 4133-4137.	
	C173	Opposition to European patent EP-B-0589877, cited opposition document D9: De La Cruz et al. "Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage", <i>J. Bio. Chem.</i> 263: 4318-4322 (1988)	
	C174	Opposition to European patent EP-B-0589877, cited opposition document D23: US 517 659 "Affymax priority document", entitled "Recombinant Library Screening Methods", priority document filed 1 May 1990 for EP-A-0 527 839 (Article 54(3) EPC)	
	C175	Complaint filed 4/23/99	
	C176	First Amended Complaint filed 5/6/99	
	C177	Defendant Cambridge Antibody Technology, Limited's Motion to Dismiss plaintiff MorPhosys Ag's Complaint filed 06/8/99	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/416,902
				Filing Date	October 13, 1999
				First Named Inventor	John McCafferty, et al.
				Group Art Unit	1639
				Examiner Name	Amber D. Steele
Sheet	11	of	11	Attorney Docket Number	05569.0004.DVUS06

	C178	Response of Plaintiff MorphoSys AG to Cambridge Antibody Technology Ltd's First Set of Interrogatories and Request for Production of Documents and Things filed 10/18/99	
	C179	Plaintiff's Supplemental Answer to Interrogatory No. 2	
	C180	Response of Plaintiff-MorphoSys AG to Cambridge Antibody Technology Ltd.'s First Set of Interrogatories and Request for Production of Documents and Things filed 3/27/00	
	C181	Response of Plaintiff MorphoSys AG to Cambridge Antibody Technology Ltd.'s Second set of Interrogatories filed 7/3/002	
	C182	Response of MorphoSys AG to Cambridge Antibody Technology's Third Set of Interrogatories filed 8/14/007	
	C183	Declaration of Edward S. Golub, Ph.D. in Support of Morpho Sys Motion for Partial Summary Judgment of Noninfringement filed 9/1/00	
	C184	Edward S. Golub, Ph.D. Curriculum Vitae	
	C185	Expert Report of Edward S. Golub, Ph.D. dated 6/00 (with Exhibit 1) E. S. Golub Curriculum Vitae-Exhibit 2 E.S. Golub Validity Report and Exhibit 3 Declaration of E.S. Golub regarding Immunological Concepts	
	C186	Rebuttal Expert Report of Edward S. Golub, Ph.D.	
	C187	Reply of Edward S. Golub, Ph.D. to Rebuttal Expert Reports of Edward P. Cohen, M.D. and Ronald II, Jackson, Ph.D. dated 08/01/00	
	C188	Declaration of Carlos F. Barbas III, Ph.D. in Support of MorphoSys Motion for Partial Summary Judgment of Noninfringement filed 9/1/00	
	C189	Carlos F. Barbas III, Ph.D. Curriculum Vitae	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.